肿瘤细胞治疗研究
FRONTIER PAPERS
Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias.
本研究提出了一种创新的表位导向方法，通过有效规避富集驱动的表位偏倚，极大地加速了功能性激动型纳米抗体的发现。我们的方法及工程化多价抗 OX40 纳米抗体为推动癌症免疫治疗策略提供了强大的平台。
CD79A/CD40 intracellular domain uses a 4-1BB-like metabolic pathway driven by cholesterol biosynthesis.
CD79A/CD40 CAR-T 细胞表现出独特的代谢适应，包括早期糖酵解激活、持续的 OXPHOS 以及胆固醇代谢上调，这些可能共同支撑其增强的增殖与持久性。靶向胆固醇代谢可能代表一种优化 CAR-T 细胞功能并改善治疗结局的新策略。
CAR-T cells with the CD38(-)CD73(-)Tim-3(-)HLA-DR(+) phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.
Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.
Limited SUMOylation inhibitor administration enhances eradication of Burkitt's lymphoma with CD19 CAR-T therapy.
Bystander CAR(-)CD8(+) T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody.
Cord Blood-Derived Fibroblast Activation Protein-Targeted Chimeric Antigen Receptor Natural Killer Cells Persist in Vivo.
Response to the Letter regarding "Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in
Long-term outcomes of chronic active Epstein-Barr virus infection in childhood after dominantly infected lymphocyte subpopulation management.
EBV 感染淋巴细胞谱分析指导 CAEBV 的长期无 HCT 控制。CD4+T 细胞型 CAEBV 需及时而非择期进行 HCT，以防疾病进展和转化。
Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
